| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Comparison of anti-CD20 and anti-CD45 antibodies for conventional and pretargeted radioimmunotherapy of B-cell lymphomas.
|
Blood
|
2002
|
1.67
|
|
2
|
A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
|
Blood
|
2009
|
1.66
|
|
3
|
Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
|
J Nucl Med
|
2003
|
1.26
|
|
4
|
Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.
|
Blood
|
2002
|
1.23
|
|
5
|
211AtCl@US-tube nanocapsules: a new concept in radiotherapeutic-agent design.
|
Small
|
2007
|
1.09
|
|
6
|
Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211.
|
Cancer Res
|
2009
|
1.08
|
|
7
|
Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.
|
Transplantation
|
2004
|
1.06
|
|
8
|
Radiohalogens for imaging and therapy.
|
Chem Soc Rev
|
2004
|
1.04
|
|
9
|
Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas.
|
Blood
|
2006
|
1.03
|
|
10
|
A streptavidin-biotin binding system that minimizes blocking by endogenous biotin.
|
Bioconjug Chem
|
2002
|
1.03
|
|
11
|
Eradication of disseminated leukemia in a syngeneic murine leukemia model using pretargeted anti-CD45 radioimmunotherapy.
|
Blood
|
2007
|
1.03
|
|
12
|
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
|
Oncol Rep
|
2007
|
1.02
|
|
13
|
Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.
|
Blood
|
2011
|
1.01
|
|
14
|
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates.
|
Blood
|
2009
|
0.99
|
|
15
|
Selective T-cell ablation with bismuth-213-labeled anti-TCRalphabeta as nonmyeloablative conditioning for allogeneic canine marrow transplantation.
|
Blood
|
2003
|
0.98
|
|
16
|
Pretargeted radioimmunotherapy for B-cell lymphomas.
|
Clin Cancer Res
|
2007
|
0.97
|
|
17
|
Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas.
|
Blood
|
2007
|
0.96
|
|
18
|
Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas.
|
Cancer Res
|
2007
|
0.96
|
|
19
|
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
|
Blood
|
2010
|
0.93
|
|
20
|
Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.
|
Blood
|
2011
|
0.89
|
|
21
|
Pilot study of a (213)bismuth-labeled anti-CD45 mAb as a novel nonmyeloablative conditioning for DLA-haploidentical littermate hematopoietic transplantation.
|
Transplantation
|
2010
|
0.85
|
|
22
|
Pretargeted radioimmunotherapy using genetically engineered antibody-streptavidin fusion proteins for treatment of non-hodgkin lymphoma.
|
Clin Cancer Res
|
2011
|
0.84
|
|
23
|
Radioimmunotherapy as non-myeloablative conditioning for allogeneic marrow transplantation.
|
Leuk Lymphoma
|
2006
|
0.83
|
|
24
|
Role of biotin-binding affinity in streptavidin-based pretargeted radioimmunotherapy of lymphoma.
|
Bioconjug Chem
|
2005
|
0.82
|
|
25
|
Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.
|
Blood
|
2013
|
0.81
|
|
26
|
Extracorporeal adsorption therapy: a method to improve targeted radiation delivered by radiometal-labeled monoclonal antibodies.
|
Cancer Biother Radiopharm
|
2008
|
0.75
|
|
27
|
Formation of sulfonamide bonds through reaction of dyes with serum proteins.
|
J Nucl Med
|
2003
|
0.75
|